GlassScriptPhysician profile
Michele D Solarte
NPI 1649626318
$1,774.44
in general payments reported to CMS, 2019-2025
21 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $144 · 2021: $205 · 2022: $75.64 · 2023: $505 · 2024: $402 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $522.67 | 2019-2025 | Clareon, Centurion, Tryptyr |
| Sight Sciences, INC. | $262.00 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Astellas Pharma US INC | $149.59 | 2023 | |
| Dompe US, INC. | $135.65 | 2022-2025 | Oxervate |
| Glaukos Corporation | $124.99 | 2020 | |
| Bausch & Lomb Americas INC. | $87.26 | 2023-2024 | Stellaris, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $67.61 | 2021-2023 | |
| Oyster Point Pharma, INC. | $45.43 | 2023-2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $44.13 | 2022-2023 | Eylea |
| Allergan, INC. | $37.59 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $35.95 | 2025 | Xdemvy |
| Amgen INC. | $34.49 | 2024-2025 | Tepezza |
| Abbvie INC. | $33.50 | 2023 | |
| Harrow Eye, LLC | $32.67 | 2024-2025 | Iheezo |
| Kala Pharmaceuticals, INC. | $31.32 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $30.05 | 2022-2023 | Cequa |
| Ocular Therapeutix, INC. | $25.81 | 2025 | Dextenza |
| Genentech USA, INC. | $21.68 | 2024 | Vabysmo |
| Thea Pharma INC. | $18.71 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $18.65 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Solarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.